Founded in 2007, Genor Biopharma Co. Ltd. (Genor BioPharma, Stock code: 6998.HK) is an innovation-driven biopharma company with a pipeline of therapies covering the world's most prevalent cancer types (breast, lung, and gastrointestinal cancer) and hematological malignancies.
Genor Biopharma strives to build an innovative, platform-oriented and integrated company with innovative drug R&D, preclinical research, clinical development, regulatory, CMC development, and commercial manufacturing.
The company has created a cutting-edge bispecific and multi-specific immune-oncology discovery platform. The industry-leading R&D center has extensive large molecule CMC (Chemistry, Manufacturing, and Controls) development experience. It is capable of developing comprehensive bioprocesses and formulations, and manufacturing preclinical and clinical materials with advanced analytical, quality control, and quality assurance systems for compliance.
The GMP commercial manufacturing facility operates with a highly GMP-compliant production team. The commercial facility employs advanced continuous-flow cell culture technologies for high-yield manufacturing (~20 g/L) as well as internally developed cell culture media for cost-effective production. The site produces Phase III and pivotal trial clinical supplies, executes commercial process validation, and performs commercial manufacturing after product launch.
Beijing office
Yuxi, Yunnan - Principally Phase 3 and commercial manufacturing
Zhangjiang, Shanghai - R&D center, QC/Analytical center, cGMP sample manufacturing
South San Francisco, US - Bi-specific platform
We aspire to become a biopharmaceutical company with global presence, serving patients and society.
Our mission is to become a biopharmaceutical engine in discovery, research, development, manufacturing and commercialization of innovative therapeutics initially for patients in China and gradually for patients globally.
Our History
December 2007
Genor Biopharma was incorporated in Shanghai as one of the first innovation-driven biopharmaceutical company.
July 2014
Yuxi Genor was incorporated in Yuxi, Yunnan, PRC
January 2015
GB242 (Infliximab Biosimiliar）received IND approval from NMPA in China.
April 2016
Manufactory facility was constructed in Yuxi, Yunan
November 2016
GB226 (Geptanolimab) received IND approval from NMPA in China
April 2017
Genor Biopharma was incorporated in Cayman Islands.
December 2018
Completed Series A Financing
September 2019
Differentiated Antibody Discovery Platform, Ab Therapeutics, was established in SF, USA
May 2020
Completed Series B Financing
June 2020
In-licensed GB491 (Lerociclib, CDK4/6 inhibitor) from G1 Therapeutics；In-licensed GB492 (IMSA101, STING agonist) from ImmuneSensor Therapeutics.
July 2020
GB226 NDA submission and received priority review status
October 2020
Genor was successfully listed on HKEX (stock code 6998.HK) and raised USD$400mn
December 2021
A number of world-renowned experts in tumor immunology & clinical oncology have been appointed as members of the Biosciences Advisory Board
February 2022
GB242 (Infliximab, biosimilar to Remicade, Jiayoujian佳佑健®) received NDA approval in the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Adult Ulcerative Colitis, Adult and Pediatric Crohn’s Disease and Fistulising Crohn’s Disease.
January-June 2022
Accelerate multiple key clinical trials
View More
June 2022
The company entered into a cooperative development agreement with Abogen to jointly develop globally innovative mRNA products and related pharmaceuticals.
